Wells Fargo & Company MN cut its position in shares of InVitae Corp (NASDAQ:NVTA) by 7.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 49,424 shares of the medical research company’s stock after selling 3,811 shares during the quarter. Wells Fargo & Company MN owned approximately 0.12% of InVitae Corp worth $472,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Donald L. Hagan LLC boosted its holdings in InVitae Corp by 30.0% during the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock worth $124,000 after purchasing an additional 3,000 shares during the last quarter. American International Group Inc. boosted its holdings in InVitae Corp by 31.3% during the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after purchasing an additional 4,090 shares during the last quarter. Credit Suisse AG boosted its holdings in InVitae Corp by 22.9% during the first quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock worth $279,000 after purchasing an additional 4,694 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in InVitae Corp by 13.9% during the first quarter. Bank of New York Mellon Corp now owns 105,549 shares of the medical research company’s stock worth $1,167,000 after purchasing an additional 12,896 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in InVitae Corp by 47.9% during the second quarter. Rhumbline Advisers now owns 42,661 shares of the medical research company’s stock worth $408,000 after purchasing an additional 13,820 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: This news story was published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/11/14/wells-fargo-company-mn-has-472000-position-in-invitae-corp-nvta.html.

Several research analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a report on Friday, August 11th. BidaskClub cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 price target (up from $14.00) on shares of InVitae Corp in a report on Wednesday, August 9th. Finally, Leerink Swann cut their price target on shares of InVitae Corp from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $13.50.

InVitae Corp (NVTA) opened at $8.20 on Tuesday. InVitae Corp has a 52 week low of $5.76 and a 52 week high of $11.88.

InVitae Corp Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InVitae Corp (NASDAQ:NVTA).

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.